Top Page
Everest Medicines Ltd.
(1952)
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
Everest Medicines Ltd. Business Overview & Revenue Model
Everest Medicines Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 851.28M | 706.68M | 125.93M | 12.79M | 54.00K | 0.00 |
| Gross Profit | 597.21M | 528.89M | 91.52M | 8.15M | 31.00K | 0.00 |
| EBITDA | -276.68M | -670.04M | -744.63M | -198.91M | -972.78M | -683.03M |
| Net Income | -658.75M | -1.04B | -844.46M | -247.28M | -1.01B | -5.68B |
Balance Sheet | ||||||
| Total Assets | 4.93B | 4.96B | 5.77B | 6.61B | 6.65B | 7.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.60B | 2.35B | 1.65B | 2.64B | 4.48B |
| Total Debt | 708.72M | 575.61M | 510.63M | 534.64M | 485.03M | 447.33M |
| Total Liabilities | 1.01B | 886.05M | 804.10M | 960.25M | 753.83M | 636.11M |
| Stockholders Equity | 3.93B | 4.07B | 4.97B | 5.65B | 5.89B | 6.84B |
Cash Flow | ||||||
| Free Cash Flow | -205.84M | -744.92M | -1.04B | -1.59B | -1.71B | -991.83M |
| Operating Cash Flow | -181.47M | -679.51M | -769.19M | -1.16B | -729.94M | -471.90M |
| Investing Cash Flow | 423.71M | 974.40M | 752.50M | -1.03B | -975.82M | -519.93M |
| Financing Cash Flow | 171.64M | 37.80M | 10.10M | -25.31M | -76.51M | 5.64B |
Everest Medicines Ltd. Technical Analysis
Everest Medicines Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$10.95B | 14.18 | 6.69% | 4.28% | -8.49% | -9.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$13.85B | -17.86 | -15.75% | ― | 102.73% | 38.42% | |
44 Neutral | HK$9.52B | -16.56 | -42.46% | ― | 1219.19% | 25.15% | |
41 Neutral | HK$16.44B | -57.23 | -8.79% | ― | 964.40% | 65.90% | |
40 Underperform | HK$20.15B | -95.47 | -3.36% | ― | 58.24% | 38.85% | |
40 Underperform | HK$9.91B | -47.34 | -21.42% | ― | 240.05% | -140.09% |
Everest Medicines Ltd. Corporate Events
Everest Medicines chairman and executive director Yifang Wu has increased his stake in the company by purchasing 30,000 shares on the open market on 31 December 2025 for about HK$1.14 million, at an average price of roughly HK$37.98 per share. The board said the on-market share purchase reflects Wu’s strong confidence in the company’s long-term prospects and development, although it cautioned existing shareholders and potential investors to exercise care when trading the stock.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines has responded to the approval of a generic version of its kidney disease drug NEFECON in China by stressing that NEFECON remains protected under a valid Chinese patent until May 2029, with the patent duly registered on the national platform for marketed drugs. Citing China’s Patent Law and the rules governing early settlement of drug patent disputes, the company warned that any manufacture, sale, promotion or import of products infringing this patent before its expiry would constitute infringement, and reminded generic applicants who have pledged not to market before patent expiry that they must honor this commitment; Everest pledged to take lawful action against suspected violations while reiterating its broader stance that robust IP enforcement is critical to fair competition, sustained innovation and continued patient access to innovative therapies in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced a significant increase in shareholding by its directors and a substantial shareholder, CBC Group. This move, involving a purchase of shares worth over HK$38 million, reflects strong confidence in the company’s future prospects and long-term development, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced a Commercialization Service Agreement with Hasten, under which its subsidiary will provide commercialization services for certain products in China. This agreement, effective from December 11, 2025, will initially last for three years with automatic renewals. The subsidiary will handle various services including distribution, marketing, and sales forecasting. A deposit of RMB100,000,000 will be paid to Hasten, refundable based on sales targets. This agreement reflects Everest Medicines’ strategic focus on expanding its market presence in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board also oversees three committees: audit, remuneration, and nomination, with specific directors assigned to each committee. This announcement provides clarity on the leadership structure of the company, potentially impacting its governance and strategic direction.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has entered into an agreement with Visara, Inc. to develop and commercialize VIS-101, a novel bifunctional biologic, in Greater China and other Asian markets. This strategic collaboration allows Everest Medicines to expand into the ophthalmology sector, adding a commercially attractive asset to its late-stage product pipeline, potentially enhancing its market positioning and addressing significant unmet medical needs in the region.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced the grant of 1,237,374 options to Mr. Yifang Wu, an executive director and chairman of the board, under the Post-IPO Share Option Scheme. This move is part of the company’s strategy to align its remuneration policy with market standards and enhance operational efficiency. The options, which have no performance targets, are set to vest equally over four years and are expected to contribute to the company’s sustainable development and good corporate governance.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced significant changes in its board of directors, effective October 10, 2025. Mr. Wei Fu has been re-designated as a non-executive director and appointed as honorary chairman, stepping down from his roles as chairman of the board and committees to focus on other business endeavors. Mr. Yifang Wu has been appointed as the new executive director and chairman, indicating a strategic leadership transition aimed at guiding the company’s future growth and operations.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. This announcement reflects the company’s commitment to strong governance and strategic oversight, which is crucial for its continued growth and competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced the grant of 74,000 options under its Post-IPO Share Option Scheme and 234,800 awards under its Pre-IPO ESOP on October 2, 2025. These grants are part of the company’s strategy to attract, retain, and incentivize employees, aligning with its remuneration policy to enhance operational efficiency. The options have a seven-year exercise period with a vesting schedule over four years, and they do not include performance targets, which the Remuneration Committee considers competitive and consistent with the company’s objectives.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.